Company intelligence / Profile preview

QRxPharma Limited

Ownership: Private
Development stage: NDA

Overview

QRxPharma developed MoxDuo IR, which reached NDA filing stage but appears to have faced regulatory challenges with the FDA. Despite initial disappointment with FDA findings in June 2012, post-submission review meetings clarified steps needed for approval without requiring additional clinical trials[5].

Therapeutic areas: Neurology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

MOXDUO

NDA

Indications: Acute pain

Partnerships

Actavis Inc. (later acquired by Watson Pharmaceuticals)Paladin Labs Inc.Aspen GroupTeva Pharmaceuticals[7]

Beyond the preview

Go deeper on QRxPharma Limited.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on QRxPharma Limited.

Explore the full profile